1 r cardiovascular endpoints and six for liver
endpoints).
2 All-cause mortality was the primary
endpoint.
3 e Categories (CPC) at 1 year was the outcome
endpoint.
4 al response score at week 12 was the primary
endpoint.
5 h PRO now represented in OWL and as a SPARQL
endpoint.
6 several weeks before the time of the primary
endpoint.
7 the dose was adjusted to attain the primary
endpoint.
8 expenditure, food intake and other metabolic
endpoints.
9 nd FibroTest were compared with histological
endpoints.
10 vaccinating children for different settings/
endpoints.
11 d progression-free survival were the primary
endpoints.
12 cataract formation were determined as safety
endpoints.
13 rate and time to recurrence were the primary
endpoints.
14 ication at month 6 were defined as secondary
endpoints.
15 , whereas 29 genes were associated with both
endpoints.
16 vine PET on cancer control and late toxicity
endpoints.
17 n FGF21 impact metabolic but not thermogenic
endpoints.
18 illages would reach prevalence and intensity
endpoints.
19 through the entire organoid, and functional
endpoints.
20 ing system was independently associated with
endpoint 1: HR, 2.14 (95% CI, 1.22-3.77).
21 ogic scoring systems on predicting composite
endpoints 1 (PSC-related death and liver transplantation
22 All patients met the primary efficacy
endpoint:
12 months after gene therapy, PDMS-2 scores we
23 hak system: HR, 1.55 [95% CI, 1.10-2.18] for
endpoint 2 and HR, 1.43 [95% CI, 1.10-1.85] for endpoint
24 95% confidence interval (CI), 1.49-6.68] for
endpoint 2 and HR, 2.05 [95% CI, 1.17-3.57] for endpoint
25 wig system: HR, 2.62 [95% CI, 1.19-5.80] for
endpoint 2 and HR, 2.06 [95% CI, 1.09-3.89] for endpoint
26 aging systems were independent predictors of
endpoints 2 and 3 (Nakanuma system: hazard ratio [HR], 3
27 point 2 and HR, 2.06 [95% CI, 1.09-3.89] for
endpoint 3).
28 point 2 and HR, 2.05 [95% CI, 1.17-3.57] for
endpoint 3; Ishak system: HR, 1.55 [95% CI, 1.10-2.18] f
29 point 2 and HR, 1.43 [95% CI, 1.10-1.85] for
endpoint 3; Ludwig system: HR, 2.62 [95% CI, 1.19-5.80]
30 igher rates of the device-oriented composite
endpoint (
3.3% [69 of 2100] vs 1.9% [23 of 1193]; RR 1.6
31 Studies reporting the primary
endpoint,
30-day post-operative stroke rate, were includ
32 s statistically improves prediction for some
endpoints,
absolute changes and impact on clinical decis
33 ted novel biomarkers and clinically relevant
endpoints across a spectrum of warm ischemic times, befo
34 atio (TBR) from the ascending aorta (primary
endpoint) (
adalimumab: TBR = 0.002, 95% confidence inter
35 he relevant endpoint (RE) and the additional
endpoint (
AE).
36 s not evident from analysis of developmental
endpoints alone, including pulsatile frequency-modulated
37 The key exploratory PRO
endpoints (
analysed for all patients who received at lea
38 The primary efficacy
endpoint,
analysed in the per-protocol population, was p
39 were classified were included in the primary
endpoint analysis.
40 ug combinations were assessed on >1 phase 2A
endpoint and only 3 were assessed in both phase 2A and 2
41 iteria for inclusion (one for cardiovascular
endpoints and six for liver endpoints).
42 recent RCT, in which ICU LOS was the primary
endpoint,
and in administrative data, we showed that add
43 rovide core principles, appropriate clinical
endpoints,
and endpoint definitions to be used in clinic
44 nt of cardiac biomarkers and other surrogate
endpoints,
and in some cases initiation of cardioprotect
45 The predefined
endpoints are 30- and 360-day complications, and shocks
46 The underlying clinical
endpoints are analysed in seasonal time periods predefin
47 the currently used endpoints, potential new
endpoints,
as well as what new markers are needed to ass
48 The primary
endpoints assessed at the end of treatment were the safe
49 ent for a device-oriented composite clinical
endpoint at 12 months in an all-comer population.
50 Study monitoring was monthly to the primary
endpoint at month 12 and then protocol-driven follow-up
51 the tight control group achieved the primary
endpoint at week 48 (56 [46%] of 122 patients) than in t
52 Treatment allocation was open label but
endpoints at 12 months were assessed by masked investiga
53 The study's primary
endpoint,
at week 24, was previously reported (combined
54 clinical events committee adjudicated safety
endpoints based on Valve Academic Research Consortium-2
55 e no significant differences in major 30-day
endpoints between the 2 groups.
56 The primary performance
endpoint,
biventricular pacing on the 12-lead electrocar
57 We aimed to establish an
endpoint capturing clinically relevant deteriorations (d
58 me measure was the device-oriented composite
endpoint (
cardiac mortality, target vessel-related myoca
59 Baseline echocardiography and a composite
endpoint (
cardiovascular mortality and hospitalization)
60 Here, we sequenced the genomes of one
endpoint clone from each population to test whether the
61 ty of tolvaptan over placebo for the primary
endpoint compared with patients with these findings.
62 le size analysis, in which g was used as the
endpoint,
compared docetaxel data with mitoxantrone data
63 Changes in composite
endpoint components were not significantly different bet
64 Secondary
endpoints consist of the development of gallstones on ul
65 text of pharmacogenetics, where the survival
endpoint could be death, disease remission or the occurr
66 Clinical
endpoints defined as hepatic decompensation (ascites, en
67 nciples, appropriate clinical endpoints, and
endpoint definitions to be used in clinical trials of PV
68 sease severity, data collection, and updated
endpoint definitions.
69 nt of disease severity, data collection, and
endpoint definitions.
70 over investigator's choice therapy (primary
endpoint;
described previously).
71 The primary
endpoint did not differ significantly between the ASV an
72 , and physiologic consequences of automated,
endpoint-
directed resuscitation systems and compare them
73 reby accelerate progress towards the desired
endpoint (
e.g., elimination) or increase the chances of
74 (serious adverse events [SAE]), and efficacy
endpoints:
ejection fraction, Minnesota Living with Hear
75 The primary
endpoint,
equivalence of overall response, was met (271
76 oice of animal models, selecting appropriate
endpoints,
ethics of informed consent, and regulatory is
77 d chemicals was determined using biochemical
endpoints,
exposure activity ratios for biological and e
78 and each OCT scan was linked to EMR clinical
endpoints extracted from EPIC.
79 of DNA damage signaling in vitro could be an
endpoint for developing whole mixture potency factors (M
80 The primary
endpoint for efficacy was biochemical response as define
81 The primary
endpoint for this study was a time-dependent composite o
82 ognostication, and to determine intermediate
endpoints for clinical trials.
83 ntrahepatic cccDNA and/or HBsAg are critical
endpoints for future antiviral therapy in chronic HBV.
84 The coprimary
endpoints for noninferiority were hemagglutination inhib
85 To address this lack, we mapped resection
endpoints genome-wide at high resolution in Saccharomyce
86 : 1.04 to 1.49; p = 0.020) and the composite
endpoint (
HR: 1.21; 95% CI: 1.05 to 1.40; p = 0.010).
87 e greatest risk of adverse outcomes: primary
endpoint (
HR: 2.21; 95% CI: 1.80 to 2.71), HF hospitaliz
88 The primary
endpoint in both populations was overall survival (defin
89 Loss of photoreceptors is a common
endpoint in degenerative retinal diseases.
90 blish the effect of MABp1 with a new primary
endpoint in patients with advanced colorectal cancer.
91 Post-hoc analysis of survival to combined
endpoint in SMA infants with 2 copies of SMN2 indicated
92 n is hampered by lack of a feasible clinical
endpoint in this population.
93 ctiveness (RBE) factors for surrogate cancer
endpoints in cell culture models and tumor induction in
94 ions and raises the question of the relevant
endpoints in clinical studies.
95 r noninvasive monitoring and as quantitative
endpoints in early intervention trials in children with
96 zes for subacute and chronic neurobehavioral
endpoints in other domains, however, were small.
97 h lower than expected, rendering the primary
endpoint inadequately powered.
98 Secondary
endpoints included IVF- and LD-related safety, such as b
99 Other
endpoints included mean number of annual injections and
100 Study
endpoints included myocardial infarction, new or worseni
101 Endpoints included noninferiority of HPV-16/18 antibodie
102 Secondary
endpoints included SSI incidence at 4 days, length of st
103 CSDS affected numerous
endpoints,
including paradoxical sleep (PS) and slow-wav
104 Although the most common
endpoint is a reduced number of eosinophils in biopsies,
105 ly changing their gait, which could bias the
endpoint measures.
106 patients in the cohort, 2616 met the primary
endpoint (
median time to event of 14.5 years) and 721 de
107 sample sizes, longer duration, or a primary
endpoint more sensitive in this pre-dementia population,
108 For the primary
endpoint,
multilevel modelling yielded significantly hig
109 patients with non-completion of the primary
endpoint,
non-compliance to treatment (ascertained by pa
110 The
endpoint occurred in 6.6% of prasugrel patients and in 5
111 At 4-year follow-up, the primary composite
endpoint occurred in 61%.
112 st independent CMR predictor of the combined
endpoint (
odds ratio: 2.73; 95% confidence interval: 1.2
113 an intention-to-treat analysis, the primary
endpoint of air leak duration was not different between
114 infection, which was defined as a composite
endpoint of bacterial pneumonia (confirmed by the endpoi
115 oeboid movement may thus constitute a common
endpoint of both EMT-dependent and EMT-independent cance
116 red with aspirin alone reduced the composite
endpoint of cardiovascular death, myocardial infarction,
117 There was no difference in the primary
endpoint of day 1 dyspnea reduction, despite significant
118 y visit was associated with risk of combined
endpoint of death or permanent invasive ventilation in S
119 ssociated with a lower risk for the combined
endpoint of HF readmission or all-cause mortality (HR: 0
120 ctors that predict relapse risk (the primary
endpoint of many pivotal clinical trials testing the eff
121 up volunteers for 24 months for the primary
endpoint of safety, assessed as local and systemic react
122 roportion of individuals meeting the primary
endpoint of seroconversion for poliovirus types 1, 2, an
123 For the key secondary
endpoint of sweat chloride concentration, the least squa
124 The predefined
endpoint of the 5-year analysis was invasive disease-fre
125 mortality rate in the liberal group (primary
endpoint of the study) was 45% (67 patients) versus 56%
126 The primary
endpoint of this trial was to establish the proportion o
127 Group differences on secondary
endpoints of disease progression measuring cognition and
128 pical corticosteroids achieved the coprimary
endpoints of IGA 0/1 (39% [125 patients] who received du
129 Currently available
endpoints of therapy are inadequate to evaluate the effi
130 examined for association with a traditional
endpoint (
overall survival) and for its potential use as
131 n this review, we discuss the currently used
endpoints,
potential new endpoints, as well as what new
132 imination index (IDI) were applied to assess
endpoint prediction.
133 Although this study did not meet its primary
endpoints,
prespecified subgroup analyses of patients wi
134 As an exploratory
endpoint,
PROs were assessed at baseline, week 9, and ev
135 llel group, superiority, open-label, blinded-
endpoint,
randomised controlled trial, patients aged 70
136 nts and a CE with 2 components: the relevant
endpoint (
RE) and the additional endpoint (AE).
137 patients, respectively, achieved the primary
endpoint (
relative risk 1.76, 95% CI 1.12-2.77, p=0.0045
138 us in vivo measurement of multiple metabolic
endpoints remains challenging.
139 s results were inconsistent with the primary
endpoint result; further research into the role of compl
140 int of bacterial pneumonia (confirmed by the
endpoint review committee), pulmonary or extrapulmonary
141 le to stimulate GSK3beta phosphorylation, an
endpoint robustly activated by the full-length receptor.
142 thout confirmed influenza, and 13 without an
endpoint sample.
143 The primary
endpoint,
sensitivity of the sentinel-lymph-node-based d
144 participants were assessable for the primary
endpoint (
sodium thiosulfate, n=49; control, n=55).
145 nventional therapy using a stringent primary
endpoint (
steroid-free clinical remission for 3 months w
146 Use of
endpoints,
such as sleep and circadian rhythm, that are
147 had deterioration in the QLQ-LC13 composite
endpoint than did chemotherapy-treated patients (46 [31%
148 n patients enrolled in the ASTIC trial using
endpoints that are traditional for clinical trials in Cr
149 us surgical procedures while exploring trial
endpoints that may be optimal for each tumor type.
150 For the primary
endpoint,
the average absolute change in LCI2.5 from bas
151 For both
endpoints,
the between-group differences were statistica
152 10(7) PFU dose, the geometric mean IgG ELISA
endpoint titre was 1624 (95% CI 1146-2302) and seroconve
153 genomes de novo fail to achieve the ultimate
endpoint to produce contigs, each representing one whole
154 ll survival) and for its potential use as an
endpoint to reduce sample size in clinical trials.
155 (the combination being our a priori primary
endpoint),
to provide context and enhance precision of p
156 prospective, randomised, open-label, blinded-
endpoint trial in adult participants with ischaemic stro
157 We evaluated these
endpoints using log-binomial regression, adjusting for t
158 were obtained at week 26 from all 25 primary
endpoint vaccine cases and 125 matched vaccine controls,
159 h 14.9 [SD=9.2]; adjusted beta=-5.91) at the
endpoint visit.
160 The primary
endpoint was >/=20% reduction in heart rate from baselin
161 The primary efficacy
endpoint was 1-year change in MLMT performance, measurin
162 The primary
endpoint was 2 year event-free survival in all registere
163 The primary
endpoint was 30-day all-cause mortality.
164 The primary
endpoint was 90-day mortality.
165 The primary
endpoint was a >/=50% improvement on the Pain Disability
166 Our primary
endpoint was a 3-year composite outcome of posttransplan
167 The primary
endpoint was a 7-point change in self-assessed dyspnea a
168 The primary efficacy
endpoint was a 75% reduction in PASI score (PASI 75) fro
169 The primary
endpoint was a composite global rank score (hierarchy of
170 The primary safety
endpoint was a composite of cardiac death, myocardial in
171 The primary
endpoint was a composite of myocardial infarction, strok
172 The primary
endpoint was a reduction by at least 35% in the spleen v
173 INTERPRETATION: The primary
endpoint was a useful means of measuring clinical perfor
174 The primary
endpoint was all-cause mortality at 30 days.
175 th from cardiovascular causes; the secondary
endpoint was all-cause mortality.
176 was death-censored graft loss, and secondary
endpoint was all-cause mortality.
177 The primary
endpoint was annualised relapse rate.
178 The primary
endpoint was annualized rate of kidney enlargement in pa
179 The primary
endpoint was assessed in all patients who received at le
180 The combined
endpoint was cardiovascular death, MI, or stroke at 1 ye
181 The primary
endpoint was change from baseline to Day 84 on a semiqua
182 The primary efficacy
endpoint was change from baseline to week 6 in the 80 mg
183 The primary
endpoint was change in 6MWD from baseline to week 48.
184 The primary
endpoint was change in Asthma Control Questionnaire (ACQ
185 The primary
endpoint was clinical cure at the test-of-cure visit (21
186 The primary efficacy
endpoint was clinically driven target lesion revasculari
187 The primary
endpoint was comparability in overall response, with equ
188 Primary
endpoint was death-censored graft loss, and secondary en
189 The imaging primary
endpoint was detection of early subclinical engraftment
190 The primary
endpoint was difference in exercise time increment betwe
191 The primary
endpoint was disease-free survival at 10 years of follow
192 The primary
endpoint was failure of the treatment strategy, defined
193 The primary
endpoint was failure, defined as death related to infect
194 The primary
endpoint was favorable neurocognitive outcome (cerebral
195 The primary
endpoint was final infarct size.
196 The primary efficacy
endpoint was global stroke recovery, which combines dich
197 The primary
endpoint was HBV reactivation, defined as detectable HBV
198 The primary
endpoint was healing rates of HD-CU at 14 days after tre
199 The primary
endpoint was incidence of grade 2 or worse stomatitis by
200 The primary
endpoint was incidence of hearing loss 4 weeks after fin
201 The primary
endpoint was independently confirmed objective response
202 Primary
endpoint was inpatient mortality.
203 The primary
endpoint was intestinal permeability in patients with sy
204 The primary
endpoint was investigator-assessed intracranial response
205 The primary
endpoint was investigator-assessed progression-free surv
206 The primary
endpoint was investigator-assessed progression-free surv
207 The primary
endpoint was ipsilateral local relapse (80% power to exc
208 The primary
endpoint was Kaplan-Meier survival to transplant.
209 e survival and overall survival; the primary
endpoint was later changed to overall survival after the
210 The primary
endpoint was met in 27 of 30 patients (90%).
211 The primary efficacy
endpoint was met with clemastine fumarate treatment, whi
212 The primary
endpoint was moderate-to-severe COPD exacerbation rate.
213 The primary
endpoint was mucosal healing (CDEIS <4) with absence of
214 The primary
endpoint was not achieved (P = 0.072); however, a greate
215 in 767 patients, the noninferiority primary
endpoint was not achieved (p value for noninferiority =
216 The primary
endpoint was ocular and systemic safety, but exploratory
217 The primary
endpoint was overall response, defined as the proportion
218 The primary
endpoint was overall survival in the intention-to-treat
219 The primary
endpoint was overall survival in the intention-to-treat
220 The primary
endpoint was overall survival, analysed by intention to
221 The primary
endpoint was oxygenation index (OI) at day 7.
222 The primary
endpoint was participation (ie, attendance at breast can
223 The primary
endpoint was percentage change from baseline in areal BM
224 Primary
endpoint was postoperative pelvic sepsis within 30 posto
225 The primary
endpoint was progression-free survival assessed by an in
226 The primary
endpoint was progression-free survival by local investig
227 The primary
endpoint was progression-free survival by local investig
228 The primary
endpoint was proportion of responders.
229 The primary
endpoint was reached in 188 patients (40%) during a medi
230 The primary
endpoint was safety and ORR.
231 In the meta-analysis, the composite
endpoint was similar between groups (hazard ratio [HR]:
232 The primary
endpoint was spleen response (defined as the proportion
233 The primary
endpoint was sustained virologic response 12 weeks after
234 The primary efficacy
endpoint was sustained virological response at post-trea
235 The primary efficacy
endpoint was the change from baseline in behavioral symp
236 The primary
endpoint was the change from baseline in total renal art
237 The primary
endpoint was the change of serum bilirubin, creatinine a
238 The primary efficacy
endpoint was the composite of all-cause mortality, myoca
239 The secondary efficacy
endpoint was the composite of cardiovascular death, myoc
240 The primary HRQoL
endpoint was the global health scale, with the predefine
241 The primary
endpoint was the incidence of serious adverse events at
242 The primary
endpoint was the mean change from baseline in the St Geo
243 The primary
endpoint was the number and percentage of adverse events
244 The primary efficacy
endpoint was the number of attacks of hereditary angio-o
245 The primary
endpoint was the occurrence of SSI within 30 days of sur
246 The primary efficacy
endpoint was the percentage of patients with a sustained
247 The primary
endpoint was the proportion of participants with less th
248 The primary
endpoint was the proportion of participants with plasma
249 The primary
endpoint was the proportion of participants with plasma
250 The primary
endpoint was the proportion of patients achieving an obj
251 The primary
endpoint was the proportion of patients in each group wi
252 The primary
endpoint was the proportion of patients in the intention
253 The primary
endpoint was the proportion of patients who attained an
254 The primary
endpoint was the rate of uncomplicated perineal wound he
255 The primary
endpoint was the time to occurrence of stroke, myocardia
256 The primary
endpoint was time to culture conversion in liquid media
257 The primary
endpoint was time to local recurrence in the resection c
258 The primary
endpoint was time to normalisation of patients' respirat
259 The primary
endpoint was time to progression (time of progressive di
260 The primary efficacy
endpoint was time to recurrence of any mood event during
261 The primary efficacy
endpoint was time-to-parasitaemia, assessed by TBS.
262 The primary
endpoint was WHO-defined radiological pneumonia with pul
263 defined as responders at 24 h (primary study
endpoint)
was 16% for tolvaptan and 20% for placebo (p =
264 l was negative for its primary and secondary
endpoints,
we did observe significant differences in mul
265 Correlates of the primary safety
endpoint were age, anemia, congestive heart failure, mul
266 eated biomarker measurements and the primary
endpoint were assessed using a joint model.
267 The main predictors for the primary
endpoint were male sex (p = 0.022), NYHA functional clas
268 Primary
endpoints were 2 quality-of-life measurements, the Kansa
269 The co-primary
endpoints were adequate relief of symptoms and stool Bif
270 Safety
endpoints were adverse events, clinical laboratory value
271 Pharmacokinetic, safety, and virology
endpoints were also assessed.
272 These
endpoints were analysed in the intention-to-treat popula
273 The secondary
endpoints were antitumor effect and safety (UMIN00000944
274 569 deaths (26.2%) and 896 (41.2%) composite
endpoints were ascertained.
275 The secondary
endpoints were changes in pruritus scores measured using
276 from whom DNA and dental and anthropometric
endpoints were collected during multiple examinations (a
277 Primary
endpoints were DSM265 safety, tolerability, and pharmaco
278 tions between AD status and cardio-metabolic
endpoints were estimated using survey weighted logistic
279 Primary
endpoints were frequency of recommending shorter (3-year
280 The primary
endpoints were maximum tolerated dose and dose-limiting
281 Coprimary
endpoints were overall survival in the intention-to-trea
282 Endpoints were patient survival +/- liver transplant and
283 Coprimary
endpoints were patients (%) achieving Investigator's Glo
284 The secondary
endpoints were physiological parameters, duration of ven
285 Secondary
endpoints were postoperative wound infection, intra-abdo
286 Co-primary
endpoints were progression-free survival and overall sur
287 Co-primary
endpoints were progression-free survival in patients wit
288 Primary
endpoints were safety and tolerability for the escalatio
289 Primary
endpoints were safety and tolerability, analysed in the
290 The primary
endpoints were safety of GSK2330672, assessed using clin
291 Endpoints were short- and long-term survival rates.
292 Endpoints were survival, life expectancy, quality-adjust
293 The key study
endpoints were technical success assessed at the end of
294 Secondary
endpoints were the change in infarct volume from baselin
295 The main
endpoints were the change in mean and median best-correc
296 The primary
endpoints were the first record of 1 of 4 cardiovascular
297 The primary
endpoints were the proportion of patients in the ITG wit
298 Primary
endpoints were the proportion of positive section margin
299 The co-primary
endpoints were treatment failure (histological progressi
300 Study
endpoints were: incidence of adverse events, incidence o